Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
about
New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L ).Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
P2860
Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@ast
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@en
type
label
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@ast
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@en
prefLabel
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@ast
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@en
P2860
P1433
P1476
Hemostatic agents of broad app ...... ing of factor Xa zymogenicity.
@en
P2093
Lacramioara Ivanciu
Rodney M Camire
P2860
P304
P356
10.1182/BLOOD-2015-03-634329
P407
P577
2015-04-20T00:00:00Z